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Abstract
 
Single and combination cytokines offer promise in some patients with advanced cancer. Many
spontaneous and experimental cancers naturally express ligands for the lectin-like type-2 trans-
membrane stimulatory NKG2D immunoreceptor; however, the role this tumor recognition
pathway plays in immunotherapy has not been explored to date. Here, we show that natural ex-
pression of NKG2D ligands on tumors provides an effective target for some cytokine-stimulated
NK cells to recognize and suppress tumor metastases. In particular, interleukin (IL)-2 or IL-12
suppressed tumor metastases largely via NKG2D ligand recognition and perforin-mediated cyto-
toxicity. By contrast, IL-18 required tumor sensitivity to Fas ligand (FasL) and surprisingly did
not depend on the NKG2D–NKG2D ligand pathway. A combination of IL-2 and IL-18 stimulated
both perforin and FasL effector mechanisms with very potent effects. Cytokines that stimulated
perforin-mediated cytotoxicity appeared relatively more effective against tumor metastases ex-
pressing NKG2D ligands. These findings indicate that a rational choice of cytokines can be
made given the known sensitivity of tumor cells to perforin, FasL, and tumor necrosis factor–
related apoptosis-inducing ligand and the NKG2D ligand status of tumor metastases.
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Introduction
 
Cytokines have played an important role in new progress
in tumor immunology and immunotherapy. The use of IL-2
in patients with metastatic melanoma and renal cell cancer
has demonstrated that manipulation of the immune system
is capable of mediating the durable regression of established
metastatic tumors (1). The mechanism of antitumor effi-
cacy of IL-2 is closely related to its ability to expand and
activate NK and T cells that express IL-2 receptors. Other
promising cytokines in cancer immunotherapy, including
IL-12 (2) and IL-18 (3) or combination IL-2/IL-18 (4),
have also been shown to mediate their antitumor activities
in mice to a large extent via NK cells. IL-12 plays an essen-
tial role in the interaction between the innate and adaptive
arms of immunity (5), produced by APC and acting upon
T cells and NK cells to generate cytotoxic lymphocytes.
IL-12 is also the major cytokine responsible for Th1 cell
differentiation, allowing potent production of IFN-
 
 
 
. IL-18
is a potent immunoregulatory cytokine that was initially
described as an IFN-
 
 
 
–inducing factor (6). IL-18 enhances
T and NK cell cytokine production, proliferation, and cy-
tolytic activity (7, 8) and the expression of Fas ligand (FasL)
and FasL- or perforin-mediated antitumor activity (9–11).
Systemic administration of IL-18 has demonstrated consid-
erable therapeutic activity in several murine tumor models
(10, 12).
Recent understanding of the means by which NK cells
kill target cells through a complex set of activating and in-
hibitory receptors recognizing corresponding ligands on tu-
mor cells has paved the way for the design of improved
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strategies for NK cell–based immunotherapy. One key ac-
tivating receptor on NK cells for the elimination of tumor
cells is NKG2D. NKG2D is present as a homodimeric re-
ceptor (13), is expressed on the cell surface of almost all
NK cells (14), and is inducible by exposure to IL-15 (15).
Several ligands, which bind to NKG2D, are structurally re-
lated to MHC class I molecules (16–18). In humans, the
polymorphic MHC class I chain–related molecules (MIC)A
and MICB can be recognized by NKG2D (19, 20). Unlike
conventional MHC class I, those MIC proteins display up-
regulated surface expression on stressed cells and are fre-
quently overexpressed by tumors (21). Although MIC
molecules have not been found in mice, the 
 
retinoic acid
early inducible-1 (Rae-1)
 
 gene products and a distantly re-
lated minor histocompatibility antigen, H60, have been re-
ported as NKG2D ligands in mice (17, 18). Mouse UL16-
binding protein-like transcript 1 (Mult1), a third relative of
this growing protein family, was identified more recently
and shown to bind NKG2D (22, 23).
Natural or induced expression of NKG2D ligands mark-
edly enhances the sensitivity of tumor cells to NK cells in
vitro (14, 17, 19, 22, 24, 25). In general, the lysis of tumor
cells that naturally express NKG2D ligands is partially inhib-
ited by NKG2D-specific antibodies, indicating that NKG2D
is an important receptor in the recognition of target cells by
NK cells but not the only one (14, 25). Indeed, some target
cells that lack expression of NKG2D ligands are nevertheless
sensitive to NK cells (14), in line with the identification of
other NK cell stimulatory receptors that participate in tu-
mor cell recognition (26). Expression of NKG2D ligands by
tumor cells also results in immune destruction in vivo. Re-
cent studies show that the ectopic expression of NKG2D
ligands, Rae-1 and H60, in several tumor cell lines resulted
in the rejection of the tumor cells, even when the tumor
cells expressed normal levels of MHC class I molecules (27,
28). Immune depletion studies showed that rejection was
dependent on NK cells and/or CD8
 
 
 
 T cells depending on
the parent tumor cell line and the dose of tumor cells that
were transferred (27). These studies together with the in vitro
studies leave little doubt that expression of NKG2D ligands
confers an effective barrier to tumor formation. Interest-
ingly, our recent study suggested that ectopic expression of
the NKG2D ligand, Rae-1
 
 
 
, in a MHC class I–deficient
tumor rendered it particularly susceptible to perforin-medi-
ated tumor rejection (29).
Despite our clear knowledge of the therapeutic value of
cytokines in promoting NK cell–mediated suppression of
tumor growth and metastases, no previous study has eluci-
dated whether direct immune recognition of tumor cells is
a requirement for cytokine efficacy. Here, we illustrate us-
ing a series of cytokines with distinct means of activating NK
cell effector function that the NKG2D–NKG2D ligand
recognition pathway is pivotal in the antimetastatic activity
of cytokines that promote perforin-mediated cytotoxicity.
This study now provides a fundamental basis for some ra-
tional selection of cytokines in NK cell–mediated therapy
of tumor metastases that either have or lack NKG2D ligand
expression.
 
Materials and Methods
 
Mice.
 
Inbred C57BL/6 and BALB/c WT mice were pur-
chased from The Walter and Eliza Hall Institute of Medical Re-
search. The following gene-targeted mice were bred at the Peter
MacCallum Cancer Centre: C57BL/6 perforin (pfp)-deficient
(B6 pfp
 
 
 
/
 
 
 
); C57BL/6 FasL mutant (B6 gld); C57BL/6 RAG-1-
deficient (B6 RAG-1
 
 
 
/
 
 
 
) (from Dr. Corcoran, The Walter and
Eliza Hall Institute of Medical Research); BALB/c IFN-
 
 
 
 
 
/
 
 
 
;
BALB/c pfp
 
 
 
/
 
 
 
; BALB/c pfp IFN-
 
 
 
 
 
/
 
 
 
; BALB/c TNF-related
apoptosis-inducing ligand (TRAIL)
 
 
 
/
 
 
 
 (from Dr. Peschon,
AMGEN, Seattle, WA) (30); and BALB/c pfp TRAIL
 
 
 
/
 
 
 
 mice.
All mice originally generated on a 129 background have been
backcrossed between 10–12 times onto the C57BL/6 or BALB/c
background. Mice of 6–12 wk of age were used in all experi-
ments that were performed according to animal experimental
ethics committee guidelines.
 
Isolation of Spleen NK Cells and Cytotoxicity Assay.
 
NK cells
were prepared from the spleen of B6 RAG-1
 
 
 
/
 
 
 
 mice as de-
scribed previously (31). Purity was always 
 
 
 
90%. The cytolytic
activity of NK cells from various cytokine-treated mice was tested
against tumor target cells by a standard 12-h 
 
51
 
Cr release assay as
described previously. In some experiments, the assay was per-
formed in the presence of neutralizing hamster anti-mNKG2D
mAb (C7) (30 
 
 
 
g/ml) or control hamster Ig (30 
 
 
 
g/ml).
 
Flow Cytometric Analysis.
 
Tumor cell lines were assessed for
NKG2D ligand expression as follows. To avoid the nonspecific
binding of mAbs to Fc
 
 
 
R, anti–mouse CD16/32 (2.4G2) mAb
was added to the mAb cocktail. After washing the cells, staining
was performed in PBS with 5% FCS and 0.02% sodium azide on
ice using the PE-conjugated NKG2D tetramer as described pre-
viously (32). Additionally, tumor cell lines were screened using
anti-pan Rae
 
 
 
 and anti-H60 antibodies (33). Anti-pan Rae-1
mAb (clone 186107, rat IgG2a isotype) reacts with Rae-1
 
 
 
, 
 
 
 
, 
 
 
 
,
 
 
 
, and 
 
 
 
 as described previously (34). The stained cells were ana-
lyzed on a FACScan (Becton Dickinson), and the data were pro-
cessed by the CELLQuest program (Becton Dickinson).
 
Tumor Cell Lines.
 
The following standard experimental
mouse tumor cell lines were employed in vitro and in vivo.
B16F10 melanoma (perforin-sensitive, FasL- and TRAIL-insen-
sitive, H-2
 
b
 
); RMA-S lymphoma (perforin-sensitive, FasL- and
TRAIL-insensitive, H-2
 
b
 
); RMA-S-Rae-1
 
 
 
 lymphoma (per-
forin-sensitive, FasL- and TRAIL-insensitive, H-2
 
b
 
); 3LL Lewis
lung carcinoma (perforin-sensitive, FasL-sensitive and TRAIL-
insensitive, H-2
 
b
 
); Renca renal cell carcinoma (perforin-, and
TRAIL-sensitive and FasL-insensitive, H-2
 
d
 
), DA3-m (mock
vector alone infected) mammary carcinoma (perforin-, FasL-, and
TRAIL-sensitive, H-2
 
d
 
), and DA3-H60 (H60 infected) mam-
mary carcinoma (perforin-, FasL-, and TRAIL-sensitive, H-2
 
d
 
).
DA3-H60 cells were prepared and selected by flow cytometry as
described previously (31). The maintenance of all tumor cell lines
and the sensitivities of lung and liver metastases to various cyto-
toxic molecules in vitro and in vivo have been described previ-
ously (35).
 
Tumor Models In Vivo.
 
3LL, Renca, DA3, and DA3-H60
tumor cell lines were inoculated i.v. at a dose indicated and pre-
viously shown to result in a maximal number of lung metastases
regardless of whether inoculation was in WT, gene-targeted, or
antibody-treated mice. The ability of each cytokine treatment
schedule was then evaluated for its ability to reduce the ex-
pected metastatic tumor burden. For all experimental metastasis
models, mice were injected i.v. with tumor cells and killed 14 d
later, the lungs removed, and surface metastases counted with
the aid of a dissecting microscope. In all metastasis models, the 
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data was recorded as the mean number of metastases 
 
 
 
 SE of
the mean.
 
Cytokine Treatment Protocols.
 
Recombinant mouse IL-12 and
IL-2 was provided by Genetics Institute and Chiron Corpora-
tion, respectively. Recombinant mouse IL-18 was provided by
Glaxo Smith Kline. The preparations of IL-2, IL-12, and IL-18
were diluted in PBS immediately before use. Some groups of
mice were treated with one of the following: (a) 500 U IL-12 i.p.
on days 3–7 after tumor inoculation; (b) 100,000 U IL-2 i.p. on
days 3–7; (c) 2 
 
 
 
g of IL-18 i.p. on days 0–4; (d) 100,000 U IL-2
i.p. on days 4, 6 and 8; (e) 2 
 
 
 
g of IL-18 i.p. on days 4–8; and (f)
schedules (d) and (e) together.
 
NK Cell Depletion and NKG2D Neutralization.
 
NK cells
were specifically depleted in B6 and BALB/c mice using 100 
 
 
 
g
i.p. rabbit anti-asialoGM1 (asGM1) antibody (Wako Chemicals)
on days 0, 1, and 7 (after tumor inoculation) as described (36).
Some groups of B6 or BALB/c mice were treated with either
hamster anti–mouse NKG2D mAb (C7 clone; reference 37) (250
 
 
 
g i.p.) or hamster control Ig mAb (250 
 
 
 
g i.p.) on days 0, 1, 7,
and 8 after tumor inoculation. It should also be noted that
NKG2D
 
 
 
 NK effector cells were not depleted by anti-NKG2D
mAb treatment (not depicted).
 
Statistical Analysis.
 
Significant differences in metastases were
determined by the unpaired Mann-Whitney U test. P values less
than 0.05 were considered significant.
 
Results
 
Experimental Tumor Cell Lines Naturally Express NKG2D
Ligands.
 
Initially we screened several experimental tumors
from BALB/c and C57BL/6 mice for their expression of
NKG2D ligands using the previously described NKG2D
tetramer (27), anti-pan Rae-1 mAb (34), and anti-H60
mAb (Fig. 1). Renca renal carcinoma was shown to express
the NKG2D ligands, Rae-1 and H60 (Fig. 1 A). Rae-1
 
 
 
expression was additionally demonstrated by flow cytome-
try, whereas Rae-1
 
 
 
 and H60 expression was confirmed by
RT-PCR (not depicted). DA3 mammary carcinoma cells
that did not naturally express NKG2D ligands were either
mock infected (Fig. 1 B) or infected with a retrovirus to ex-
press H60 (Fig. 1 C). The C57BL/6 3LL lung carcinoma
was shown to strongly express the NKG2D ligands (Fig. 1
D). By contrast, B16F10 melanoma and RMA-S lym-
phoma cells did not express NKG2D ligands (Fig. 1, E and
F). We have reported previously the ectopic expression of
Rae-1
 
 
 
 in RMA-S tumor cells (29) (Fig. 1 G).
 
Critical Contribution of NKG2D to Perforin-mediated Tumor
Suppression by IL-2 or IL-12.
 
Having established which
experimental tumors expressed NKG2D ligands, we next
set about defining the role the NKG2D–NKG2D ligand
Figure 1. Experimental tumor cell lines naturally express NKG2D ligands.
Tumor cell lines were stained with NKG2D tetramer (tetramer), anti-pan
Rae-1 mAb and anti-H60 antibody as indicated: (A) Renca; (B) DA3;
(C) DA3-H60; (D) 3LL; (E) B16F10; (F) RMA-S; and (G) RMA-S-
Rae-1 . Solid black lines, test; gray lines, control (control tetramer, isotype).
The data shown are representative of three independent experiments.
Figure 2. IL-2 suppresses tumor metastases via NK cell perforin and
NKG2D. Groups of 5 to 10 WT, RAG-1 / , pfp / , IFN-  / , or
pfp / IFN-  /  mice were inoculated i.v. with 105 Renca tumor cells on
day 0. Some groups of mice, as indicated, received anti-NKG2D mAb or
control Ig (250  g i.p.) on days 0, 1, 7, and 8 or anti-asGM1 (100  g i.p.)
on days 0, 1 and 7 after tumor inoculation. Mice were untreated (dotted
bars) or received IL-2 (solid bars) (100,000 U i.p. on days 3, 4, 5, 6, and 7).
The lungs were removed from mice on day 14 and the metastatic nodules
quantified. Data are recorded as the mean   SEM with the significance of
IL-2 efficacy (*P   0.05) and significance of anti-NKG2D mAb inhibition
(**P   0.05) recorded as defined by a Mann-Whitney U test. 
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pathway was potentially playing in cytokine-mediated con-
trol of tumor growth in vivo. Experiments were performed
by challenging mice with a dose of Renca tumor cells that
would metastasize equivalently in untreated WT, NK cell–
depleted WT mice, or other gene-targeted mice (Fig. 2).
Treatment with a course of IL-2 (from day 3 to 7 after tu-
mor inoculation) was effective in WT and RAG-1
 
 
 
/
 
 
 
mice, reducing metastatic load from 
 
 
 
300 to 100 me-
tastases, but IL-2 was completely ineffective in NK cell–
depleted mice (Fig. 2). Interestingly, part of the effective-
ness of IL-2 was mediated via the NKG2D–NKG2D ligand
pathway since there were a significantly higher number of
Renca lung metastases in anti-NKG2D–treated WT mice
compared with control Ig-treated WT mice. In a similar
fashion, anti-NKG2D–treated RAG-1
 
 
 
/
 
 
 
 mice had a sig-
nificantly higher number of Renca lung metastases com-
pared with control Ig-treated RAG-1
 
 
 
/
 
 
 
 mice (not de-
picted). We next assessed the effector mechanisms used by
IL-2–activated NK cells to determine whether they were
NKG2D dependent. We had shown previously that IL-2–
mediated antimetastatic activity against Renca lung me-
tastases was dependent on perforin and IFN-
 
 
 
 (38). Consis-
tent with these previous observations, IL-2 was less effec-
tive in perforin- or IFN-
 
 
 
–deficient mice and completely
inactive in mice gene targeted for both perforin and IFN-
 
 
 
(Fig. 2). Interestingly, anti-NKG2D mAb only increased
metastases in IL-2–treated WT and IFN-
 
 
 
–deficient mice
and not in perforin-deficient mice (Fig. 2). In a similar
manner, IL-12 (from day 3 to 7 after tumor inoculation)
very significantly reduced the number of Renca lung
metastases in WT and RAG-1
 
 
 
/
 
 
 
 but not in NK cell–
depleted mice (Fig. 3). Once again anti-NKG2D mAb sig-
nificantly reduced the efficacy of IL-12. IL-12 was less
effective in perforin-, TRAIL-, or IFN-
 
 
 
–deficient mice
and completely inactive in mice gene targeted for both per-
forin and TRAIL, consistent with our previous report (38)
(Fig. 3). Anti-NKG2D mAb only increased metastases in
IL-12–treated WT and TRAIL-deficient mice and not
perforin-deficient mice (Fig. 3). Therefore, two different
cytokines that promote NK cell perforin-mediated activity
suppress metastases in large part via the NKG2D pathway.
Figure 3. IL-12 suppresses tumor metastases via NK cell perforin and
NKG2D. Groups of 5 to 10 WT, RAG-1 / , pfp / , IFN-  / ,
TRAIL / , pfp / IFN-  / , or pfp / TRAIL /  mice were inoculated
i.v. with 105 Renca tumor cells on day 0. Some groups of mice, as indi-
cated, received anti-NKG2D mAb or control Ig (250  g i.p.) on days 0,
1, 7, and 8 or anti-asGM1 (100  g i.p.) on days 0, 1, and 7 after tumor
inoculation. Mice were untreated (dotted bars) or received IL-12 (solid
bars) (500 U i.p. on days 3, 4, 5, 6, and 7). The lungs were removed from
mice on day 14 and the metastatic nodules quantified. Data are recorded
as the mean   SEM with the significance of IL-12 efficacy (*P   0.05)
and significance of anti-NKG2D mAb inhibition (**P   0.05) recorded
as defined by a Mann-Whitney U test.
Figure 4. IL-18 suppresses tumor metastases via NK cell FasL and in-
dependently of NKG2D. Groups of 5 to 10 WT, RAG-1 / , pfp / , or
gld mice were inoculated i.v. with 5   105 3LL tumor cells on day 0.
Some groups of mice, as indicated, received anti-NKG2D mAb or con-
trol Ig (250  g i.p.) on days 0, 1, 7, and 8 or anti-asGM1 (100  g i.p.) on
days 0, 1, and 7 after tumor inoculation. Mice were untreated (dotted
bars) or received IL-18 (solid bars) (2  g i.p. on days 0, 1, 2, 3, and 4).
The lungs were removed from mice on day 14 and the metastatic nodules
quantified. Data are recorded as the mean   SEM, with the significance
of IL-18 efficacy (*P   0.05) and significance of anti-NKG2D mAb inhi-
bition (**P   0.05) recorded as defined by a Mann-Whitney U test.Smyth et al.  1329
IL-18 Therapy Suppresses Tumor Metastases via NK Cell
FasL and Independently of NKG2D. IL-18 enhances NK
cell cytokine production, proliferation, and cytolytic activ-
ity and the expression of FasL and FasL- or perforin-medi-
ated antitumor activity (9–11). Given the relatively poor
activity of IL-18 alone against Renca tumor metastases, we
next assessed the antimetastatic activity of IL-18 alone (day
0–4 after tumor inoculation) against 3LL lung carcinoma
(Fig. 4). 3LL tumor cells are sensitive to both perforin- and
FasL-dependent pathways (35) and were thus chosen as a
tumor target for IL-18 therapy. The activity of IL-18 was
moderate but reproducible, and mediated by NK cells
rather than T or B cells (Fig. 4). Only a minor increase in
3LL lung metastases was observed in anti-NKG2D mAb–
compared with control Ig-treated mice. IL-18 treatment
was significantly less effective in FasL mutant gld mice and
slightly less so in perforin-deficient mice (Fig. 4). Anti-
NKG2D mAb only slightly increased metastases in IL-18–
treated WT and gld mice but not perforin-deficient mice.
Collectively, these data suggested that the NKG2D path-
way was essential for IL-2– and IL-12–mediated antimeta-
static activity but not IL-18–mediated antitumor activity.
Combined IL-2/IL-18 Therapy Suppresses Tumor Metastases
via NK Cell FasL and Perforin. Previous reports had indi-
cated that IL-2 and IL-18 were effective in combination
(39), and our data suggested that this combination might
engage several distinct effector pathways that were tumor
suppressive. Therefore, we examined a single or combined
treatment regime with IL-2 and IL-18 against 3LL lung
carcinoma. Strikingly, the IL-2/IL-18 combination was ex-
tremely effective at suppressing lung metastases compared
with treatment with IL-2 or IL-18 alone (Fig. 5 A). Nota-
bly, this combination required NK cells but not T and B
cells (Fig. 5 A). The extremely potent antimetastatic activ-
ity of IL-2/IL-18 was significantly reduced in gld mice and
completely inhibited in perforin-deficient mice treated
with anti-FasL mAb (Fig. 5 B). These data suggested IL-2/
IL-18 may be a particularly effective combination because
both FasL and perforin mechanisms are being employed.
Once again anti-NKG2D mAb increased metastases in WT
and gld mice but not perforin-deficient mice (Fig. 5 B). In
summary, these experiments illustrated that cytokine thera-
pies could be tailored to suppress tumor metastases depend-
ing on the sensitivity of the tumor to perforin, TRAIL, or
FasL and its expression of NKG2D ligands.
Cytokine-activated NK Cells Kill Tumors in an NKG2D-
dependent Manner. To assess the relative contribution of
NKG2D to NK cell–mediated cytotoxicity toward 3LL tu-
mor cells following these cytokine protocols, NK cells were
isolated from RAG-1 /  mice 24 h after the last cytokine
treatment and NK cell–mediated killing examined in a 12-h
cytotoxicity assay. Basal NK cell–mediated cytotoxicity was
restricted against 3LL, B16F10 (Fig. 6 A), and TAP-2–defi-
cient RMA-S tumor cells (not depicted); however, RMA-
S-Rae-1  targets were considerably more sensitive to NK
cell–mediated cytotoxicity, and this was inhibited by anti-
NKG2D mAb (Fig. 6 A). IL-2 treatment enhanced NK
cell–mediated cytotoxicity of 3LL and B16F10 target cells,
and the majority of IL-2–enhanced cytotoxicity against 3LL
was inhibited by anti-NKG2D mAb (Fig. 6 A). IL-2 also
enhanced NK cell–mediated cytotoxicity of RMA-S-Rae-
1  (Fig. 6 A) and RMA-S (not depicted) tumor cells, and
anti-NKG2D mAb only inhibited lysis of the RMA-S-Rae-
1 –expressing target cells (Fig. 6 A). A very similar pattern
was observed with NK cells from IL-12–treated mice (Fig. 6
B). Collectively, these data indicated that a large proportion
of IL-2– or IL-12–stimulated NK cell cytotoxicity against
NKG2D ligand expressing tumor cells was NKG2D depen-
dent. By contrast, the cytotoxicity of NK cells from IL-18–
treated mice was not inhibited by anti-NKG2D mAb (Fig. 6
C). Notably, FasL-sensitive 3LL and RMA-S-Rae-1  tu-
Figure 5. Combination IL-2/IL-18 potently suppresses tumor me-
tastases via perforin and FasL. (A) Groups of 5 to 10 WT or RAG-1 / 
mice were inoculated i.v. with 5   105 3LL tumor cells on day 0. Some
groups of WT mice, as indicated, received anti-asGM1 (100  g i.p.) on
days 0, 1, and 7 after tumor inoculation. (B) Groups of 5 WT, pfp / , or
gld mice were inoculated i.v. with 5   105 3LL tumor cells on day 0.
Some groups of mice, as indicated, received anti-NKG2D mAb (solid bars)
or control Ig (dotted bars) (250  g i.p.) on days 0, 1, 7, and 8 or anti-FasL
(250  g i.p.) on days 0, 1 and 7 after tumor inoculation. Mice in A and B
were untreated or received IL-2 alone (100,000 U i.p. on days 4, 6, and 8)
and IL-18 alone (2  g i.p. on days 4, 5, 6, 7, and 8) or the combination
(IL-2/IL-18). The lungs were removed from mice on day 14 and the meta-
static nodules quantified. Data are recorded as the mean   SEM with the
significance of cytokine efficacy (*P    0.05) and significance of anti-
NKG2D mAb inhibition (**P   0.05) recorded as defined by a Mann-
Whitney U test. Regardless of whether in the presence of control Ig or
anti-NKG2D mAb, groups of pfp /  and gld mice or WT and pfp / 
mice treated with anti-FasL, recorded a similar level of metastases (range
137   4 to 145   5 metastases) to WT control mice (not depicted).NKG2D Regulates Perforin Function In Vivo 1330
mor cells were more sensitive to IL-18–stimulated NK cells
than FasL-resistant B16F10 tumor cells. These preliminary
data supported the concept that IL-18–stimulated NK cells
were capable of FasL-mediated cytotoxicity and that this
pathway was not NKG2D dependent. In concert with the
potent antimetastatic activity of the IL-2/IL-18 combina-
tion, IL-2/IL-18–stimulated NK cells were extremely cyto-
toxic toward all the tumor target cells and anti-NKG2D
mAb partially neutralized lysis of NKG2D ligand expressing
3LL and RMA-S-Rae-1  target cells (Fig. 6 D).
Tumors Expressing NKG2D Ligands Are More Sensitive
to Cytokines That Promote Perforin-mediated Cytotoxicity.
Given that IL-12 and IL-18 cytokine therapies mediated
their NK cell–mediated suppression of metastases by very
distinct mechanisms, we next assessed whether tumors ex-
pressing NKG2D ligands might be relatively more sensitive
to IL-12 than IL-18. To compare cytokine activity against
matched tumor cells that lack or express a NKG2D ligand,
we used DA3 and DA3-H60, the perforin-, FasL-, and
TRAIL-sensitive mammary tumors. The growth of DA3-
H60 was naturally suppressed in WT mice compared with
DA3 tumors (Fig. 7 A). In preliminary experiments, we es-
tablished that H60 could stimulate natural host NK cell
perforin–mediated protection when overexpressed in DA3
tumor cells (Fig. 7 B). Therefore, for cytokine therapy we
chose doses of DA3 and DA3-H60 that each generated
 100 metastases in WT mice (Fig. 7 C). Although IL-18
had an equivalent effect in suppressing DA3 and DA3-H60
Figure 6. Some cytokine-activated NK cells kill tumors in an NKG2D-dependent manner. Spleen NK cells were isolated (day 0) from B6 RAG-1 / 
mice 24 h after treatment with: PBS (control) and (A) IL-2 (100,000 U i.p. on days –5,–4,–3,–2,–1); (B) IL-12 (500 U i.p. on days –5,–4,–3,–2,–1);
(C) IL-18 (2  g i.p. on days –5, –4, –3, –2, –1); or (D) IL-2/IL-18 (IL-2 100,000 U i.p. on days –5,–3, –1 and IL-18 2  g i.p. on days –5, –4, –3, –2, –1).
Their cytotoxic activities were tested against 3LL, B16F10, RMA-S-Rae1 , and RMA-S (not depicted) tumor cells in the presence of 30  g/ml of anti-
mNKG2D mAb or 30  g/ml of control hamster Ig by 12 h 51Cr release assay at several effector:target ratios (100:1 to 12.5:1 shown). Data are repre-
sented as the mean   SEM of triplicate samples. Similar results were obtained in two independent experiments.Smyth et al.  1331
tumor metastases in WT mice, IL-12 was far more effec-
tive against DA3-H60 than against DA3 tumor (Fig. 7 C).
As expected, IL-12–mediated suppression of DA3-H60
metastases was perforin dependent, and IL-18–mediated
suppression of DA3-H60 and DA3 tumor metastases was
FasL dependent (Fig. 7 C). NK cells were more cytotoxic
to DA3-H60 than DA3 tumor cells (Fig. 8 A). The selec-
tive effect of IL-12 on DA3-H60 cells was supported by
the increased cytotoxicity of spleen NK cells from IL-12–
treated mice against DA3-H60 target cells (Fig. 8 A). By
contrast, NK cells from IL-18–treated mice were equiva-
lently cytotoxic toward DA3 and DA3-H60 target cells
and anti-NKG2D mAb was without effect (Fig. 8 B).
Discussion
Here we have shown that cytokine therapies that medi-
ate their NK cell activity via FasL or TRAIL do not de-
pend on the NKG2D–NKG2D ligand pathway but require
sensitivity of the tumor cells to the appropriate death re-
ceptor pathway. By contrast, those cytokines that employ
perforin appear more effective against tumor metastases ex-
pressing NKG2D ligands. This contention was supported
by the ability of IL-18 to equivalently suppress tumor me-
tastases independently of their expression of the NKG2D
ligand H60, whereas IL-12 more effectively suppressed the
same tumor expressing H60 in a perforin-dependent man-
ner. Our previous analysis had suggested that ectopic ex-
pression of NKG2D ligands in the NK cell–sensitive
RMA-S and RMA tumor cells triggered natural perforin-
mediated immunity (29). This study is the first to illustrate
the importance of endogenous NKG2D ligand expression
by tumor metastases during cytokine therapy. Herein we
have clearly shown in models of NK cell–mediated sup-
pression that the perforin-mediated therapeutic activity of
cytokines such as IL-2 and IL-12 is mediated in large part
via NKG2D–NKG2D ligand pathway. With knowledge of
the relative sensitivity of a tumor to perforin, TRAIL, and
FasL and its expression of NKG2D ligands, it should be
possible to rationally deliver single and combine cytokine
therapies to maximum effect.
Expression of NKG2D ligands may be controlled by var-
ious stresses such as heat, retinoids, and carcinogens (40,
Figure 7. Tumors expressing NKG2D ligands
are more sensitive to cytokines that promote perforin-
mediated cytotoxicity. (A) Groups of 5 WT mice
were inoculated i.v. on day 0 with increasing doses
of DA3 tumor cells (dotted bars) or DA3-H60 tumor
cells (solid bars) as indicated. (B) At a dose of 105
tumor cells, metastases were additionally examined
in pfp /  mice or WT mice treated with anti-asGM1
(100  g i.p.) on days 0, 1, and 7 after tumor inocu-
lation. (C) Groups of 5 WT or pfp /  mice were
inoculated i.v. on day 0 with either 105 DA3 tumor
cells or 106 DA3-H60 tumor cells. Some groups of
WT mice, as indicated in the legend, received anti-
FasL (250  g i.p.) on days 0, 1, and 7 after tumor
inoculation. Mice were untreated (control) or re-
ceived the following cytokine therapies: IL-12
(solid bars) (500 U i.p. on days 3, 4, 5, 6, and 7) or
IL-18 (striped bars) (2  g i.p. on days 0, 1, 2, 3, and
4). The lungs were removed from mice on day 14
and the metastatic nodules quantified. Data are re-
corded as the mean   SEM.
Figure 8. IL-12–activated NK cells potently kill tumors expressing
H60 ligand. Spleen NK cells were isolated (day 0) from BALB/c RAG-1 / 
mice 24 h after treatment with: (A) IL-12 (500 U i.p. on days –5, –4, –3,
–2, –1); or (B) IL-18 (2  g i.p. on days –5, –4, –3, –2, –1). Their cyto-
toxic activities were tested against DA3 and DA3-H60 tumor cells in the
presence or absence of 30  g/ml of anti-mNKG2D mAb or 30  g/ml
of control hamster Ig as indicated by 12 h 51Cr release assay at several
effector:target ratios (100:1 to 12.5:1 shown). Data are represented as the
mean   SEM of triplicate samples. Similar results were obtained in two
independent experiments.NKG2D Regulates Perforin Function In Vivo 1332
41). Expression of MIC-A and MIC-B by DC has also
been reported to be induced by IFN-  (42). The signaling
events that are responsible for the up-regulation of Rae-1
or H60 expression by tumor cells are not known. Although
the tumors employed in our study are unlikely to respond
to cytokines IL-2 and IL-12 directly, it remains possible
that bystander inflammatory effects of systemic levels of
these cytokines may indirectly promote NKG2D ligand
expression in the treated mice. This potential mechanism
is inherently complicated to examine; however, arguing
against such an effect, it appeared that the NKG2D path-
way was not important in cytokine control of tumors that
did not express detectable NKG2D ligands in vitro. The
expression of NKG2D itself on NK cells does not appear to
be modulated by these cytokines (unpublished data).
Previous studies have determined the capacity of NKG2D
ligands, Rae-1 , Rae-1 , MULT-1, and H60 in stimulat-
ing NK cell and CD8  T cell–mediated rejection of tu-
mors in vivo (27, 28, 43). This is the first study to describe
the potency of H60 in triggering NK cell antitumor func-
tion a syngeneic BALB/c background. Clearly, ectopic ex-
pression of H60 was sufficient to stimulate NK cell–medi-
ated suppression of DA3 mammary tumor metastases. So
far, there is no evidence that this NKG2D ligand induces
qualitatively and quantitatively distinct biological effects in
responding NK cells, though this remains a possibility to be
formally tested. H60 and Rae-1  expression in B16F10
and RMA tumor cells appeared quantitatively equivalent in
a previous study; however, this was performed in a
C57BL/6 background, where H60 is a minor alloantigen
(27). Minimally, the various ligands for NKG2D might be
predicted to differ quantitatively in their effects based on
the marked differences in their affinity for NKG2D (44).
For example, synapse requirements for lymphocyte-medi-
ated cytotoxicity are minimal (45), and triggering granule
exocytosis may not require the same interaction time as
required to stimulate cytokine secretion. Nonetheless, at
present the relevance of NKG2D ligand affinity has not
been documented. We note that blockade of anti-NKG2D
may influence other activation pathways triggered in cyto-
kine-activated NK cells, since NKG2D has the ability to
costimulate multiple NK cell activation receptors (37).
Thus, other receptors that trigger perforin-mediated killing
may also be affected by inhibition of the NKG2D pathway.
The NK cell activation receptors that control the activity of
TNF superfamily death ligands remain to be determined.
Clearly, NKG2D ligand expression by tumor cells may
not be a barrier to tumor growth since many primary tu-
mors and tumor cell lines naturally express NKG2D ligands
(17, 21, 25). It is possible that tumor cells often express in-
sufficient levels of NKG2D ligands to stimulate tumor re-
jection, either because expression of the ligands is not suffi-
cient early in the development of the tumor or because
tumor cells with lower levels of ligand expression are se-
lected by the immune system in vivo as the tumor evolves.
Direct experimentation has shown that less tumor rejection
occurred when tumors only expressed intermediate levels
of Rae1 (27). Ligand-expressing tumors might also evolve
mechanisms to evade NKG2D-mediated immunity, as ex-
emplified by human tumors that often produce a soluble
version of MICA that reaches high levels in the serum,
thereby inhibiting NKG2D in T cells and possibly other
immune system cells (46, 47). There is also some indication
that circulating soluble MIC in the cancer patients deacti-
vates NK cell immunity by down-modulating important
activating and chemokine receptors (48).
Human and mouse ligands for NKG2D are also ex-
pressed in cells infected with viruses (49) or bacteria (50).
NK cells may also detect infected cells via their expression
of NKG2D ligands (22, 51). Indeed viruses encode proteins
that prevent NKG2D ligand expression and favor escape
(52, 53). The role that the NKG2D–NKG2D ligand path-
way plays in pathogen clearance is of particular interest
given our observations. Pathogens themselves are recog-
nized via TLRs expressed predominantly on APC-like
DCs (54). TLR signaling in some APC induces ligands for
the NKG2D receptor (55). All three cytokines, IL-2, IL-
12, and IL-18, are products of DCs. Thus, it will be impor-
tant to establish whether distinct TLR stimulate IL-18 ver-
sus IL-2 and IL-12 secretion, since during infection it is
possible that these endogenous cytokines have very differ-
ent roles in modulating NK cell effector function, engaging
the NKG2D pathway, and altering the outcome of NK
cell–DC interactions.
Unstimulated NK cells mainly express the long isoform
of NKG2D (NKG2DL), which associates with DNAX-
activating protein of 10 kD (DAP10) and not DAP12 and,
therefore, is predicted to activate the phosphatidylinositol
3-kinase–initiated pathway. NK cells from untreated mice
lack the NKG2DS isoform and, therefore, presumably lack
NKG2D–DAP12 complexes (56). Cytokine-activated (e.g.,
IL-2) NK cells have been shown previously to express
the short isoform of NKG2D (NKG2DS), which asso-
ciates with both DAP12 and DAP10. Long term culture
in the presence of IL-2 results in the down-regulation of
expression of both isoforms of NKG2D, especially the
short form, indicating that NKG2D in these cells mainly
signals through DAP10. Activation of killing and cytokine
release occurs when both the DAP10- and DAP12-associ-
ated forms are activated; however, the DAP10-associated
form of NKG2D might be sufficient to activate killing
(56). In this context, the C7 mAb might be blocking the
costimulatory function of NKG2D in cytokine-activated
NK cells (37). The cytotoxicities of freshly isolated NK
cells and NK cells from cytokine-activated mice were both
inhibited by the C7 anti-NKG2D mAb suggesting that
primary NKG2D pathways were also sensitive to the mAb
neutralization. We have shown that the C7 mAb blocks
DAP10-deficient NK cell killing of Rae1- –transfected
cells (57). This killing is presumably due to NKG2D that is
coupled to DAP12 and would further support the conten-
tion that the C7 mAb blocks primary stimulation by
NKG2D. Nevertheless, the relative importance of the dif-
ferent NKG2D isoforms and their adaptors in the antitu-Smyth et al.  1333
mor activity of cytokine-activated NK cells remains to be
elucidated.
Selection of future cancer patients for IL-18 therapy
should consider the FasL sensitivity of their tumors; how-
ever, NKG2D ligand status is not likely to influence respon-
siveness. High dose IL-2 has had spectacular effects in a small
fraction of patients with melanoma and renal cell cancer (1).
Given our experimental data, it will be critical to retrospec-
tively assess tumor NKG2D ligand expression and secretion
in the large number of nonresponders and responders that
have taken part in previous clinical trials of IL-2.
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